Corporate Profile
CervoMed is a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of debilitating neurodegenerative diseases. CervoMed is currently developing neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB) and certain other major neurological disorders.
News Releases
March 28, 2024
Events
Apr 11, 2024 12:45 PM EDT
Apr 4, 2024 9:40 AM EDT
Apr 3, 2024 3:25 PM EDT